Health · Medical Research · 1 hr ago
Once-daily pill lowered LDL cholesterol by nearly 65% in a trial
Enlicitide lowered LDL cholesterol by nearly 65% in a trial of adults who were already taking statins.
The once-daily pill, also called Lipfendra, is approved by the US Food and Drug Administration.
It is the first oral drug in a class of PCSK9 treatments that was previously available only as injections.
LDL cholesterol can build up in artery walls and raise the risk of heart attacks and strokes, while some people need more treatment than statins provide.
The pill works by blocking a protein so the liver can remove more LDL cholesterol from the blood.
Trials found side effects were generally similar to placebo, though one study of people with inherited high cholesterol reported more diarrhea and dizziness.
Patients must take it in the morning on an empty stomach and wait at least 30 minutes before eating.
A trial is still testing whether it prevents heart attacks and strokes, and longer-term monitoring will help establish its safety.
The once-daily pill enlicitide lowered LDL cholesterol by nearly 65% in a trial involving adults already taking statins.
A review found reductions of 57.1% to 64.6% after 24 weeks across clinical trials.
The US Food and Drug Administration approved enlicitide on July 16, 2026, making it the first oral medication in a class of treatments previously available only as injections.
In the largest trial, adverse effects occurred at similar rates among people taking enlicitide and those taking a placebo.
Researchers have not yet determined whether the pill prevents heart attacks or strokes.
- Who
- Adults with elevated cholesterol, including people already taking statins, took part in the trials.
- What
- Enlicitide, marketed as Lipfendra, lowered LDL cholesterol by nearly 65% in a trial of adults already taking statins.
- When
- The FDA approved it on July 16, 2026. The review reported results after 24 weeks.
- Where
- The trials’ locations are not stated.
- Why
- The medication is intended to lower LDL cholesterol by blocking PCSK9, which helps the liver remove cholesterol from the blood.
This story does not have two clearly opposing sides.
The FDA approved enlicitide.
The review’s search of medical research covered studies through this date.
The review of enlicitide research was published in Annals of Pharmacotherapy.
SciTechDaily published its report on the pill and trial results.
- LDL reduction
- 57.1% to 64.6% after 24 weeks across clinical trials
- Direct comparison
- About 65% reduction with enlicitide, 28% with ezetimibe and 6% with bempedoic acid
- FDA approval
- July 16, 2026
- Dosing
- Once daily in the morning on an empty stomach; wait at least 30 minutes before food or other beverages
- List price
- $315 for a 30-day supply
- Reference
- Annals of Pharmacotherapy review published October 14, 2026